-
1
-
-
84857893209
-
Genetic and epigenetic complexity in myeloproliferative neoplasms
-
Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011;2011: 208-14
-
(2011)
Hematology Am Soc Hematol Educ Program
, vol.2011
, pp. 208-214
-
-
Cross, N.C.1
-
2
-
-
84890328032
-
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
-
Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-405
-
(2013)
N Engl J Med
, vol.369
, pp. 2391-2405
-
-
Nangalia, J.1
Massie, C.E.2
Baxter, E.J.3
-
3
-
-
84890372480
-
Somatic mutations of calreticulin in myeloproliferative neoplasms
-
Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-90
-
(2013)
N Engl J Med
, vol.369
, pp. 2379-2390
-
-
Klampfl, T.1
Gisslinger, H.2
Harutyunyan, A.S.3
-
4
-
-
84902665945
-
-
United States full prescribing information. Jakafi (ruxolitinib).
-
United States full prescribing information. Jakafi (ruxolitinib). 2011. Available from: http:/www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202192lbl.pdf
-
(2011)
-
-
-
5
-
-
84902665946
-
-
EMA Summary of Product Characteristics. Jakavi. Novartis Pharmaceuticals U K Ltd [Accessed 12 March 2014]
-
EMA Summary of Product Characteristics. Jakavi. Novartis Pharmaceuticals U K Ltd. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002464/WC500133223.pdf [Accessed 12 March 2014]
-
-
-
-
6
-
-
77950684805
-
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms
-
Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17
-
(2010)
Blood
, vol.115
, pp. 3109-3117
-
-
Quintas-Cardama, A.1
Vaddi, K.2
Liu, P.3
-
7
-
-
84857837774
-
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
-
Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
-
(2012)
N Engl J Med
, vol.366
, pp. 787-798
-
-
Harrison, C.1
Kiladjian, J.-J.2
Al-Ali, H.K.3
-
8
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
-
(2012)
N Engl J Med
, vol.366
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
-
9
-
-
84865735256
-
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
-
Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155-9
-
(2012)
Nature
, vol.489
, pp. 155-159
-
-
Koppikar, P.1
Bhagwat, N.2
Kilpivaara, O.3
-
10
-
-
84859643082
-
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
-
Deshpande A, Reddy MM, Schade GO, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012;26:708-15
-
(2012)
Leukemia
, vol.26
, pp. 708-715
-
-
Deshpande, A.1
Reddy, M.M.2
Schade, G.O.3
-
11
-
-
80053014000
-
The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers
-
Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 2011;51:1644-54
-
(2011)
J Clin Pharmacol
, vol.51
, pp. 1644-1654
-
-
Shi, J.G.1
Chen, X.2
McGee, R.F.3
-
12
-
-
84880321287
-
Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)
-
Chen X, Williams WV, Sandor V, Yeleswaram S. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol 2013;53:721-30
-
(2013)
J Clin Pharmacol
, vol.53
, pp. 721-730
-
-
Chen, X.1
Williams, W.V.2
Sandor, V.3
Yeleswaram, S.4
-
13
-
-
78049412594
-
Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans
-
Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos 2010;38:2023-31
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 2023-2031
-
-
Shilling, A.D.1
Nedza, F.M.2
Emm, T.3
-
14
-
-
84861806284
-
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers
-
Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 2012;52:809-18
-
(2012)
J Clin Pharmacol
, vol.52
, pp. 809-818
-
-
Shi, J.G.1
Chen, X.2
Emm, T.3
-
15
-
-
84901007488
-
Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I
-
abstract 396
-
Verstovsek S, Mesa RA, Gotlib J, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood 2013;122:abstract 396
-
(2013)
Blood
, vol.122
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
-
16
-
-
84891303523
-
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
-
Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-53
-
(2013)
Blood
, vol.122
, pp. 4047-4053
-
-
Cervantes, F.1
Vannucchi, A.M.2
Kiladjian, J.J.3
-
17
-
-
84897528714
-
Impact of ruxolitinib on the natural history of primary myelofibrosis: A comparison of the DIPSS and the COMFORT-II cohorts
-
[Epub ahead of print]
-
Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-II cohorts. Blood 2014. [Epub ahead of print]
-
(2014)
Blood
-
-
Passamonti, F.1
Maffioli, M.2
Cervantes, F.3
-
18
-
-
84896997474
-
A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis
-
Vannucchi AM, KantarjIan H, Kiladjian J-J, et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Blood 2013;122:2820
-
(2013)
Blood
, vol.122
, pp. 2820
-
-
Vannucchi, A.M.1
Kantarjian, H.2
Kiladjian, J.-J.3
-
19
-
-
84897566182
-
Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy
-
Thiele J, Bueso-Ramos CE, Sun W, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013;122:4055
-
(2013)
Blood
, vol.122
, pp. 4055
-
-
Thiele, J.1
Bueso-Ramos, C.E.2
Sun, W.3
-
20
-
-
84889852354
-
Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
-
Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013;98:1872-6
-
(2013)
Haematologica
, vol.98
, pp. 1872-1876
-
-
Wilkins, B.S.1
Radia, D.2
Woodley, C.3
-
21
-
-
84893733177
-
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
-
Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120:513-20
-
(2014)
Cancer
, vol.120
, pp. 513-520
-
-
Verstovsek, S.1
Passamonti, F.2
Rambaldi, A.3
-
22
-
-
0034781481
-
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
-
Spiekermann K, Biethahn S, Wilde S, et al. Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol 2001;67(2):63-71
-
(2001)
Eur J Haematol
, vol.67
, Issue.2
, pp. 63-71
-
-
Spiekermann, K.1
Biethahn, S.2
Wilde, S.3
-
23
-
-
84861216420
-
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
-
Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012;119:4614-18
-
(2012)
Blood
, vol.119
, pp. 4614-4618
-
-
Eghtedar, A.1
Verstovsek, S.2
Estrov, Z.3
-
24
-
-
84868528389
-
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia (ALL)
-
Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia (ALL). Blood 2012;120(17):3510-18
-
(2012)
Blood
, vol.120
, Issue.17
, pp. 3510-3518
-
-
Maude, S.L.1
Tasian, S.K.2
Vincent, T.3
-
25
-
-
84891365474
-
Jakpot! new small molecules in autoimmune and inflammatory diseases
-
Ghoreschi K, Gadina M. Jakpot! new small molecules in autoimmune and inflammatory diseases. Exp Dermatol 2014;23:7-11
-
(2014)
Exp Dermatol
, vol.23
, pp. 7-11
-
-
Ghoreschi, K.1
Gadina, M.2
-
27
-
-
84890462687
-
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
-
Verstovsek S, Gotlib J, Gupta V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 2013;7:13-21
-
(2013)
Onco Targets Ther
, vol.7
, pp. 13-21
-
-
Verstovsek, S.1
Gotlib, J.2
Gupta, V.3
-
28
-
-
84886405838
-
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
-
Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 2013;6:81
-
(2013)
J Hematol Oncol
, vol.6
, pp. 81
-
-
Talpaz, M.1
Paquette, R.2
Afrin, L.3
-
29
-
-
84878233090
-
Expand: A phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 x 109/L and 99 x 109/L
-
Harrison CN, Gisslinger H, Miller CB, et al. Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 x 109/L and 99 x 109/L. ASH Annual Meeting Abstracts 2012;120:177
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
, pp. 177
-
-
Harrison, C.N.1
Gisslinger, H.2
Miller, C.B.3
-
30
-
-
77956696835
-
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
-
Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
-
(2010)
N Engl J Med
, vol.363
, pp. 1117-1127
-
-
Verstovsek, S.1
Kantarjian, H.2
Mesa, R.A.3
-
31
-
-
83155182714
-
Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis
-
Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188-91
-
(2011)
Mayo Clin Proc
, vol.86
, pp. 1188-1191
-
-
Tefferi, A.1
Pardanani, A.2
-
32
-
-
84877618100
-
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1, 2 inhibitor
-
Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1, 2 inhibitor. Chest 2013;143:1478-9
-
(2013)
Chest
, vol.143
, pp. 1478-1479
-
-
Wysham, N.G.1
Sullivan, D.R.2
Allada, G.3
-
33
-
-
84881416684
-
Bilateral toxoplasmosis retinitis associated with ruxolitinib
-
Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 2013;369:681-3
-
(2013)
N Engl J Med
, vol.369
, pp. 681-683
-
-
Goldberg, R.A.1
Reichel, E.2
Oshry, L.J.3
-
34
-
-
84891853911
-
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
-
Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014;28:225-7
-
(2014)
Leukemia
, vol.28
, pp. 225-227
-
-
Caocci, G.1
Murgia, F.2
Podda, L.3
-
35
-
-
84902665947
-
Hepatitis B virus reactivation associated with ruxolitinib
-
[Epub ahead of print]
-
Shen CH, Hwang CE, Chen YY, Chen CC. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 2013. [Epub ahead of print]
-
(2013)
Ann Hematol
-
-
Shen, C.H.1
Hwang, C.E.2
Chen, Y.Y.3
Chen, C.C.4
-
36
-
-
84880323178
-
Progressive multifocal leukoencephalopathy associated with ruxolitinib
-
Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013;369:197-8
-
(2013)
N Engl J Med
, vol.369
, pp. 197-198
-
-
Wathes, R.1
Moule, S.2
Milojkovic, D.3
-
37
-
-
84887193830
-
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
-
Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013;122:1192-202
-
(2013)
Blood
, vol.122
, pp. 1192-1202
-
-
Heine, A.1
Held, S.A.2
Daecke, S.N.3
-
38
-
-
84893773351
-
Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
-
Massa M, Rosti V, Campanelli R, et al. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia 2014;28:449-51
-
(2014)
Leukemia
, vol.28
, pp. 449-451
-
-
Massa, M.1
Rosti, V.2
Campanelli, R.3
-
39
-
-
84902677082
-
The Pan-JAK inhibitor ruxolitinib impairs T-cell activation, cytokine production and proliferation in vivo and in vitro
-
Stuebig T, Wolschke C, Alchalby H, et al. The Pan-JAK inhibitor ruxolitinib impairs T-cell activation, cytokine production and proliferation in vivo and in vitro. Blood 2013;122:2001
-
(2013)
Blood
, vol.122
, pp. 2001
-
-
Stuebig, T.1
Wolschke, C.2
Alchalby, H.3
-
40
-
-
84902665937
-
CD4+ T cell functions are potently suppressed by the janus kinase 1/2 (JAK1/JAK2) inhibitor ruxolitinib
-
Yajnanarayana SP, Cornez I, Heine A, et al. CD4+ T cell functions are potently suppressed by the janus kinase 1/2 (JAK1/JAK2) inhibitor ruxolitinib. Blood 2013;122:2281
-
(2013)
Blood
, vol.122
, pp. 2281
-
-
Yajnanarayana, S.P.1
Cornez, I.2
Heine, A.3
-
41
-
-
84902665938
-
JAK inhibition reduces CD25 high CD27+ FOXp3+ T regulatory cells and causes a silencing of T effector cells in patients with myeloproliferative neoplasms whilst promoting a TH17 phenotype
-
Keohane C, Kordasti SY, Seidl T, et al. JAK inhibition reduces CD25 high CD27+ FOXp3+ T regulatory cells and causes a silencing of T effector cells in patients with myeloproliferative neoplasms whilst promoting a TH17 phenotype. Blood 2013;122:4092
-
(2013)
Blood
, vol.122
, pp. 4092
-
-
Keohane, C.1
Kordasti, S.Y.2
Seidl, T.3
-
42
-
-
84902657461
-
The JAK1/JAK2 inhibitor ruxolitinib substantially affects NK cell biology
-
Schonberg K, Rudolph J, Cornez I, et al. The JAK1/JAK2 inhibitor ruxolitinib substantially affects NK cell biology. Blood 2013;122:16
-
(2013)
Blood
, vol.122
, pp. 16
-
-
Schonberg, K.1
Rudolph, J.2
Cornez, I.3
-
43
-
-
0027360333
-
An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection
-
Flynn JL, Chan J, Triebold KJ, et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993;178(6): 2249-54
-
(1993)
J Exp Med
, vol.178
, Issue.6
, pp. 2249-2254
-
-
Flynn, J.L.1
Chan, J.2
Triebold, K.J.3
-
44
-
-
84902655958
-
Efficacy of ruxolitinib in Korean myelofibrosis patients and cases complicated TB lymphadenitis during the treatment
-
Kim Y-K, Lee SR, Park Y, et al. Efficacy of ruxolitinib in Korean myelofibrosis patients and cases complicated TB lymphadenitis during the treatment. Blood 2013;122:1596
-
(2013)
Blood
, vol.122
, pp. 1596
-
-
Kim, Y.-K.1
Lee, S.R.2
Park, Y.3
-
45
-
-
84892882122
-
Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis?
-
Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 2013;122:3843-4
-
(2013)
Blood
, vol.122
, pp. 3843-3844
-
-
Heine, A.1
Brossart, P.2
Wolf, D.3
-
46
-
-
84879840304
-
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
-
Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 2013;162:229-39
-
(2013)
Br J Haematol
, vol.162
, pp. 229-239
-
-
Harrison, C.N.1
Mesa, R.A.2
Kiladjian, J.J.3
-
47
-
-
84896739915
-
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
-
Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2014;99(2):292-8
-
(2014)
Haematologica
, vol.99
, Issue.2
, pp. 292-298
-
-
Mesa, R.A.1
Kiladjian, J.J.2
Verstovsek, S.3
-
48
-
-
84886769072
-
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report
-
Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report. Blood 2013;122(8):1395-8
-
(2013)
Blood
, vol.122
, Issue.8
, pp. 1395-1398
-
-
Tefferi, A.1
Cervantes, F.2
Mesa, R.3
-
49
-
-
84885642905
-
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
-
Jovanovic JV, Ivey A, Vannucchi AM, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 2013;27:2032-9
-
(2013)
Leukemia
, vol.27
, pp. 2032-2039
-
-
Jovanovic, J.V.1
Ivey, A.2
Vannucchi, A.M.3
-
50
-
-
84886056764
-
Ruxolitinib for the treatment of myelofibrosis: A NICE single technology appraisal
-
Wade R, Rose M, Neilson AR, et al. Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal. Pharmacoeconomics 2013;31: 841-52
-
(2013)
Pharmacoeconomics
, vol.31
, pp. 841-852
-
-
Wade, R.1
Rose, M.2
Neilson, A.R.3
-
51
-
-
84896937999
-
Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate-or high-risk myelofibrosis (MF) post-polycythemia vera (PV) MF or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: Interim results from a phase II study (JAKARTA-2)
-
Harrison CN, Schaap NP, Zweegman S, et al. Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate-or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: interim results from a phase II study (JAKARTA-2). Blood 2013;122:661
-
(2013)
Blood
, vol.122
, pp. 661
-
-
Harrison, C.N.1
Schaap, N.P.2
Zweegman, S.3
-
52
-
-
77649227181
-
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: Results of a European LeukemiaNet (ELN) consensus process
-
Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 2010;148:961-3
-
(2010)
Br J Haematol
, vol.148
, pp. 961-963
-
-
Barosi, G.1
Birgegard, G.2
Finazzi, G.3
-
53
-
-
80052184481
-
Safety and efficacy of everolimus a mTOR inhibitor as single agent in a phase 1/2 study in patients with myelofibrosis
-
Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118(8):2069-76
-
(2011)
Blood
, vol.118
, Issue.8
, pp. 2069-2076
-
-
Guglielmelli, P.1
Barosi, G.2
Rambaldi, A.3
-
54
-
-
84875032119
-
A phase i study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
-
Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 2013;161:68-75
-
(2013)
Br J Haematol
, vol.161
, pp. 68-75
-
-
Mascarenhas, J.1
Lu, M.2
Li, T.3
-
55
-
-
84901013438
-
A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), or post-essential thrombocythemia MF (PET-MF): Identification of the recommended phase 2 dose
-
Harrison CN, Heidel FH, Kiladjian J-J, et al. A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (PMF), post-polycythemia vera MF (PPV-MF), or post-essential thrombocythemia MF (PET-MF): identification of the recommended phase 2 dose. Blood 2013;122:4045
-
(2013)
Blood
, vol.122
, pp. 4045
-
-
Harrison, C.N.1
Heidel, F.H.2
Kiladjian, J.-J.3
-
57
-
-
84902652715
-
Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: A preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by goelams-FIM in collaboration with the Sfgmtc
-
Robin M, Francois S, Huynh A, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by goelams-FIM in collaboration with the Sfgmtc. Blood 2013;122:306
-
(2013)
Blood
, vol.122
, pp. 306
-
-
Robin, M.1
Francois, S.2
Huynh, A.3
-
58
-
-
84905680277
-
JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
-
[Epub ahead of print]
-
Stübig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia 2014. [Epub ahead of print]
-
(2014)
Leukemia
-
-
Stübig, T.1
Alchalby, H.2
Ditschkowski, M.3
|